NewAmsterdam Pharma Company N.V. $NAMS Position Increased by Deutsche Bank AG

Key Points

• Deutsche Bank AG significantly increased its stake in NewAmsterdam Pharma by 2,634%, owning 72,397 shares valued at approximately $1.48 million after acquiring an additional 69,749 shares in the first quarter.
• Institutional investors now own 89.89% of NewAmsterdam Pharma, with various firms, including DCF Advisers and Zurcher Kantonalbank, also raising their stakes during the same period.
• NewAmsterdam Pharma reported an earnings per share (EPS) of ($0.15), surpassing analysts' expectations and highlighting a significant revenue of $19.15 million for the quarter compared to an estimate of $1.44 million.

Deutsche Bank AG lifted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 2,634.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 72,397 shares of the company's stock after acquiring an additional 69,749 shares during the period. Deutsche Bank AG owned 0.07% of NewAmsterdam Pharma worth $1,482,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. DCF Advisers LLC grew its position in shares of NewAmsterdam Pharma by 93.0% during the first quarter. DCF Advisers LLC now owns 172,500 shares of the company's stock worth $3,531,000 after acquiring an additional 83,100 shares during the last quarter. Bryce Point Capital LLC bought a new position in NewAmsterdam Pharma in the 1st quarter valued at about $438,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after buying an additional 3,390 shares in the last quarter. HB Wealth Management LLC grew its position in NewAmsterdam Pharma by 28.9% in the 1st quarter. HB Wealth Management LLC now owns 11,247 shares of the company's stock valued at $230,000 after buying an additional 2,519 shares in the last quarter. Finally, Arizona State Retirement System bought a new position in NewAmsterdam Pharma in the 1st quarter valued at about $215,000. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS traded down $0.52 on Thursday, reaching $23.95. The company's stock had a trading volume of 874,692 shares, compared to its average volume of 800,993. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.29. The stock has a market cap of $2.70 billion, a PE ratio of -14.78 and a beta of -0.02. The firm's 50 day moving average is $22.17 and its two-hundred day moving average is $20.33.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Insider Activity

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 8,269 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $24.86, for a total transaction of $205,567.34. Following the completion of the sale, the chief accounting officer directly owned 15,000 shares of the company's stock, valued at approximately $372,900. This represents a 35.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the company's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the sale, the insider directly owned 119,302 shares of the company's stock, valued at $2,897,845.58. This represents a 29.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 12,835 shares of company stock valued at $248,134 and sold 256,881 shares valued at $5,445,954. 20.84% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price for the company. Wells Fargo & Company assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday. They issued an "overweight" rating and a $45.00 target price for the company. Finally, Citigroup started coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price for the company. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $41.55.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.